Cytokinetics Grants 64,110 Stock Options, 42,496 RSUs to 18 New Employees

By Public Technologies
  • Cytokinetics granted stock options covering 64,110 common shares and 42,496 restricted stock units to 18 employees on November 13, 2026.
  • Recipients began employment in October and November 2026; restricted stock units will settle in common shares upon vesting.
  • Restricted stock units vest over three years: 40% on each of the first two grant anniversaries, then 20% on the third.
  • Stock options vest over four years: 25% after one year, then 1/48 of underlying shares monthly over the next 36 months.
  • Both awards require continued service for vesting; the options have a 10-year term.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cytokinetics Incorporated published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611161600PRIMZONEFULLFEED9878729) on November 16, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.